Blurbs

Maxim Group Thinks Virpax Pharmaceuticals’ Stock is Going to Recover

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Virpax Pharmaceuticals (VRPXResearch Report), with a price target of $4.00. The company’s shares closed last Tuesday at $1.54, close to its 52-week low of $1.19.

According to TipRanks.com, Rahman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -31.3% and a 22.4% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., Processa Pharmaceuticals, and Galmed Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Virpax Pharmaceuticals with a $4.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Virpax Pharmaceuticals’ market cap is currently $18.39M and has a P/E ratio of -1.02.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Virpax Pharmaceuticals Inc is a preclinical-stage pharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management.

Read More on VRPX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed